
## **Rodrigo Jover**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8972737/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2022, 20, 611-621.e9.	4.4	17
2	Definition of competence standards for optical diagnosis of diminutive colorectal polyps: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy, 2022, 54, 88-99.	1.8	30
3	Lynch-like Syndrome: Potential Mechanisms and Management. Cancers, 2022, 14, 1115.	3.7	8
4	Factors Associated with Withdrawal Time in European Colonoscopy Practice: Findings of the European Colonoscopy Quality Investigation (ECQI) Group. Diagnostics, 2022, 12, 503.	2.6	1
5	Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. British Journal of Cancer, 2022, , .	6.4	2
6	Factors Associated with Polyp Detection Rate in European Colonoscopy Practice: Findings of The European Colonoscopy Quality Investigation (ECQI) Group. International Journal of Environmental Research and Public Health, 2022, 19, 3388.	2.6	3
7	Familial colorectal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2022, 58-59, 101798.	2.4	2
8	Epigenome-Wide DNA Methylation Profiling of Normal Mucosa Reveals HLA-F Hypermethylation as a Biomarker Candidate for Serrated Polyposis Syndrome. Journal of Molecular Diagnostics, 2022, 24, 674-686.	2.8	1
9	Effects of Somatic Methylation in Colonic Polyps on Risk of Developing Metachronous Advanced Colorectal Lesions. Cancers, 2021, 13, 246.	3.7	4
10	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 2682-2683.	4.4	0
11	Evolución del microbioma intestinal en un proceso de transferencia de microbiota fecal (TMF) en un paciente con infección por Clostridioides difficile: análisis por NGS con diferentes programas bioinformáticos. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 184-187.	0.5	3
12	Recomendaciones de la Sociedad Valenciana de PatologÃa Digestiva sobre uso de consultas no presenciales y telemedicina. GastroenterologÃa Y HepatologÃa, 2021, , .	0.5	0
13	Effectiveness of a Multicomponent Group Psychological Intervention Program in Patients with Inflammatory Bowel Disease: A Randomized Trial. International Journal of Environmental Research and Public Health, 2021, 18, 5439.	2.6	9
14	When and How To Use Endoscopic Tattooing in the Colon: An International Delphi Agreement. Clinical Gastroenterology and Hepatology, 2021, 19, 1038-1050.	4.4	9
15	Implementation of European Society of Gastrointestinal Endoscopy (ESGE) recommendations for small-bowel capsule endoscopy into clinical practice: Results of an official ESGE survey. Endoscopy, 2021, 53, 970-980.	1.8	8
16	Colonoscopy quality across Europe: a report of the European Colonoscopy Quality Investigation (ECQI) Group. Endoscopy International Open, 2021, 09, E1456-E1462.	1.8	11
17	Artificial intelligence in small bowel capsule endoscopy ―current status, challenges and future promise. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 12-19.	2.8	50
18	xDEEP-MSI: Explainable Bias-Rejecting Microsatellite Instability Deep Learning System in Colorectal Cancer. Biomolecules, 2021, 11, 1786.	4.0	7

#	Article	IF	CITATIONS
19	Variation in Colonoscopy Performance Measures According to Procedure Indication. Clinical Gastroenterology and Hepatology, 2020, 18, 1216-1223.e2.	4.4	22
20	Personalizing Polypectomy Techniques Based on Polyp Characteristics. Clinical Gastroenterology and Hepatology, 2020, 18, 2859-2867.	4.4	12
21	Clinical and Pathological Characterization of Lynch-Like Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 368-374.e1.	4.4	23
22	Efficacy and Tolerability of High- vs Low-Volume Split-Dose Bowel Cleansing Regimens for Colonoscopy: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 1454-1465.e14.	4.4	53
23	Validation of miR-1228-3p as Housekeeping for MicroRNA Analysis in Liquid Biopsies from Colorectal Cancer Patients. Biomolecules, 2020, 10, 16.	4.0	9
24	Colorectal Cancer Screening in the Novel Coronavirus Disease-2019 Era. Gastroenterology, 2020, 159, 1998-2003.	1.3	25
25	Clinical significance of a microRNA signature for the identification and predicting prognosis in colorectal cancers with mucinous differentiation. Carcinogenesis, 2020, 41, 1498-1506.	2.8	2
26	Risk of Cancer in Family Members of Patients with Lynch-Like Syndrome. Cancers, 2020, 12, 2225.	3.7	6
27	Diagnostic yield of early repeat colonoscopy after suboptimal bowel preparation in a fecal immunochemical test-based screening program. Endoscopy, 2020, 52, 1093-1100.	1.8	7
28	Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020. Endoscopy, 2020, 52, 687-700.	1.8	255
29	Principles for Evaluation of Surveillance After Removal of Colorectal Polyps: Recommendations From the World Endoscopy Organization. Gastroenterology, 2020, 158, 1529-1533.e4.	1.3	11
30	Increased Th17-Related Cytokine Serum Levels in Patients With Multiple Polyps of Unexplained Origin. Clinical and Translational Gastroenterology, 2020, 11, e00143.	2.5	1
31	High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome. Endoscopy, 2019, 51, 142-151.	1.8	26
32	Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019. Endoscopy, 2019, 51, 775-794.	1.8	309
33	Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2019, 51, 877-895.	1.8	157
34	Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2019, 51, 1082-1093.	1.8	80
35	Effects of Family History on Relative and Absolute Risks for Colorectal Cancer: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 2657-2667.e9.	4.4	42
36	Endoscopic surveillance after colonic polyps and colorrectal cancer resection. 2018 update. GastroenterologÃa Y HepatologÃa (English Edition), 2019, 42, 188-201.	0.1	1

#	Article	IF	CITATIONS
37	New and Recurrent Colorectal Cancers After Resection: a Systematic Review and Meta-analysis of Endoscopic Surveillance Studies. Gastroenterology, 2019, 156, 1309-1323.e3.	1.3	35

28 Quality indicators and patient satisfaction in colonoscopy. GastroenterologÃa Y HepatologÃa (English) Tj ETQq0 0 8 rgBT /Overlock 10 T

39	Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy, 2019, 51, 266-277.	1.8	45
40	IDDF2019-ABS-0111â€Colorectal cancers detected following surgery at anastomoses or other colorectal locations during colonoscopy surveillance – a systematic review and meta-analysis. , 2019, , .		0
41	Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clinical and Translational Gastroenterology, 2019, 10, e00003.	2.5	53
42	Indicadores de calidad y satisfacción de los pacientes en la colonoscopia. GastroenterologÃa Y HepatologÃa, 2019, 42, 73-81.	0.5	3
43	Vigilancia tras resección de pólipos de colon y de cáncer colorrectal. Actualización 2018. GastroenterologÃa Y HepatologÃa, 2019, 42, 188-201.	0.5	21
44	<i>TFAP2E</i> Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal Cancer. Clinical Cancer Research, 2018, 24, 2820-2827.	7.0	6
45	Importance of endoscopist quality metrics for findings at surveillance colonoscopy: The detectionâ€surveillance paradox. United European Gastroenterology Journal, 2018, 6, 622-629.	3.8	16
46	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 718-725.	2.8	34
47	Detection of serrated lesions in proximal colon by simulated sigmoidoscopy vs faecal immunochemical testing in a multicentre, pragmatic, randomised controlled trial. United European Gastroenterology Journal, 2018, 6, 1527-1537.	3.8	7
48	GuÃa de práctica clÃnica. Diagnóstico y prevención del cáncer colorrectal. Actualización 2018. GastroenterologÃa Y HepatologÃa, 2018, 41, 585-596.	0.5	81
49	Adoption of colonoscopy quality measures across Europe: the European Colonoscopy Quality Investigation (ECQI) Group experience. United European Gastroenterology Journal, 2018, 6, 1106-1107.	3.8	7
50	Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PLoS ONE, 2018, 13, e0203051.	2.5	35
51	Colonoscopy quality requisites for selecting surveillance intervals: A World Endoscopy Organization Delphi Recommendation. Digestive Endoscopy, 2018, 30, 750-759.	2.3	18
52	A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples. Clinical Epigenetics, 2018, 10, 53.	4.1	44
53	Why attempt en bloc resection of non-pedunculated colorectal adenomas? A systematic review of the prevalence of superficial submucosal invasive cancer after endoscopic submucosal dissection. Gut, 2018, 67, 1464-1474.	12.1	61
54	Genetic profile of polyps and risk of advanced metachronous lesions Journal of Clinical Oncology, 2018, 36, 555-555.	1.6	0

#	Article	IF	CITATIONS
55	Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability, and CIMP status: Prognostic implications and response to chemotherapy Journal of Clinical Oncology, 2018, 36, 668-668.	1.6	0
56	Risk stratification of individuals with low-risk colorectal adenomas using clinical characteristics: a pooled analysis. Gut, 2017, 66, 446-453.	12.1	28
57	Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy, 2017, 49, 270-297.	1.8	831
58	Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy, 2017, 49, 378-397.	1.8	533
59	Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Gastroenterology, 2017, 153, 106-112.e2.	1.3	28
60	Sa1110 High Cleansing Efficacy of Ner1006 Also in the Elderly: Post Hoc Subgroup Analysis of Randomized Phase 3 Trials. Gastrointestinal Endoscopy, 2017, 85, AB195.	1.0	0
61	Colorectal Cancer Incidence in Lynch Syndrome Patients: First Report of a Multicenter Nation-Wide Study. Gastroenterology, 2017, 152, S552.	1.3	3
62	Annual Fecal Immunochemical Testing is as Effective as Colonoscopy Every 5 Years for Familial Colorectal Cancer Screening. Gastroenterology, 2017, 152, S542.	1.3	3
63	Critical Flicker Frequency Predicts Progression among Stages of Cirrhosis. Journal of Clinical and Experimental Hepatology, 2017, 7, S62.	0.9	0
64	Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. United European Gastroenterology Journal, 2017, 5, 309-334.	3.8	149
65	Correlation between adenoma detection rate in colonoscopy―and fecal immunochemical testingâ€based colorectal cancer screening programs. United European Gastroenterology Journal, 2017, 5, 255-260.	3.8	46
66	Colorectal cancer screening: with pain, no gain. Endoscopy, 2017, 49, 1031-1032.	1.8	0
67	Tu1017 Pilot Results of the ECQI Self-Assessment Questionnaire to Evaluate Quality in Colonoscopy in Europe. Gastrointestinal Endoscopy, 2017, 85, AB541.	1.0	0
68	Genetic Profile of Polyps and Risk of Advanced Metachronous Lesions. Gastroenterology, 2017, 152, S541.	1.3	0
69	Cost-Effectiveness of Surveillance Guidelines for Patients with Low-Risk or High-Risk Colorectal Adenomas. Gastroenterology, 2017, 152, S535-S536.	1.3	0
70	Reply. Gastroenterology, 2017, 153, 1693-1694.	1.3	0
71	KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia. PLoS ONE, 2017, 12, e0184937.	2.5	26
72	Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy. World Journal of Gastroenterology, 2016, 22, 3516.	3.3	30

#	Article	IF	CITATIONS
73	Surveillance after colorectal polyp removal. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 937-948.	2.4	10
74	Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair–Proficient Stage II Colon Cancer. Clinical Cancer Research, 2016, 22, 3488-3498.	7.0	26
75	Requirements and standards facilitating quality improvement for reporting systems in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy, 2016, 48, 291-294.	1.8	55
76	Mo1685 Rate of Detection of Serrated Lesions in Proximal Colon by Simulated Sigmoidoscopy: Comparison With Colonoscopy and Faecal Immunochemical Testing in a Multicentre, Pragmatic, Randomised Controlled Trial. Gastroenterology, 2016, 150, S750-S751.	1.3	1
77	Su1673 Importance of the Endoscopist Quality Metrics on the Findings at Surveillance Colonoscopy. The Detection-Surveillance Paradox. Gastrointestinal Endoscopy, 2016, 83, AB389.	1.0	1
78	Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy, 2016, 48, 571-578.	1.8	90
79	European Society of Gastrointestinal Endoscopy – Establishing the key unanswered research questions within gastrointestinal endoscopy. Endoscopy, 2016, 48, 884-891.	1.8	14
80	Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines. Endoscopy, 2016, 48, 995-1002.	1.8	21
81	1065 Incidence of Colonic Neoplasia in Patients With Serrated Polyposis Syndrome Who Undergo Endoscopic Surveillance: A Multicenter Study. Gastroenterology, 2016, 150, S210.	1.3	0
82	Su2046 BRAF and KRAS Mutations in Colonic Polyps As Molecular Marker of Risk of Metachronous Advanced Neoplasia. Gastroenterology, 2016, 150, S620.	1.3	0
83	Association of a let-7 miRNA binding region of <i>TGFBR1</i> with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis, 2016, 37, 751-758.	2.8	16
84	678 Role of Genetic Profiles on Prognosis and Prediction of Chemotherapy Benefit. Gastroenterology, 2016, 150, S140.	1.3	0
85	Reporting systems in gastrointestinal endoscopy: Requirements and standards facilitating quality improvement: European Society of Gastrointestinal Endoscopy position statement. United European Gastroenterology Journal, 2016, 4, 172-176.	3.8	38
86	Endoscopist characteristics that influence the quality of colonoscopy. Endoscopy, 2016, 48, 241-247.	1.8	42
87	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease, 2016, 48, 542-551.	0.9	23
88	Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut, 2016, 65, 1829-1837.	12.1	93
89	Serrated Polyposis Syndrome. , 2016, , 43-60.		0
90	European Colonoscopy Quality Investigation Group: Improving Standards in Colonoscopy Through a Practice Level Audit Tool. American Journal of Gastroenterology, 2016, 111, S179.	0.4	0

#	Article	IF	CITATIONS
91	Endoscopic surveillance in patients with multiple (10–100) colorectal polyps. Endoscopy, 2015, 48, 56-61.	1.8	1
92	Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer. Cancer, 2015, 121, 1395-1404.	4.1	51
93	Prevalence of <i>MLH1</i> constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer. Journal of Medical Genetics, 2015, 52, 498-502.	3.2	28
94	Minimal Hepatic Encephalopathy and Critical Flicker Frequency Are Associated With Survival of Patients With Cirrhosis. Gastroenterology, 2015, 149, 1483-1489.	1.3	108
95	Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer. PLoS ONE, 2015, 10, e0127591.	2.5	37
96	IGFBP3 Methylation Is a Novel Diagnostic and Predictive Biomarker in Colorectal Cancer. PLoS ONE, 2014, 9, e104285.	2.5	49
97	Prevalence and Characteristics of <i>MUTYH</i> -Associated Polyposis in Patients with Multiple Adenomatous and Serrated Polyps. Clinical Cancer Research, 2014, 20, 1158-1168.	7.0	57
98	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. Clinical Gastroenterology and Hepatology, 2014, 12, 1708-1716.e4.	4.4	13
99	New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Human Molecular Genetics, 2014, 23, 3506-3512.	2.9	135
100	Multiple Sporadic Colorectal Cancers Display a Unique Methylation Phenotype. PLoS ONE, 2014, 9, e91033.	2.5	9
101	The MLH1 c.1852_1853delinsGC (p.K618A) Variant in Colorectal Cancer: Genetic Association Study in 18,723 Individuals. PLoS ONE, 2014, 9, e95022.	2.5	7
102	Clinical Subtypes and Molecular Characteristics of Serrated Polyposis Syndrome. Clinical Gastroenterology and Hepatology, 2013, 11, 705-711.	4.4	36
103	470 TFAP2E Methylation and Expression Status Do Not Serve As Predictors of Response to 5-FU Based Chemotherapy in Colorectal Cancer. Gastroenterology, 2013, 144, S-84-S-85.	1.3	0
104	Effect of Aspirin and Antiplatelet Drugs on the Outcome of the Fecal Immunochemical Test. Mayo Clinic Proceedings, 2013, 88, 683-689.	3.0	24
105	Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Gastrointestinal Endoscopy, 2013, 77, 381-389.e1.	1.0	125
106	Risk of Cancer in Cases of Suspected Lynch Syndrome Without Germline Mutation. Gastroenterology, 2013, 144, 926-932.e1.	1.3	189
107	Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointestinal Endoscopy, 2013, 78, 333-341.e1.	1.0	62
108	Genetic susceptibility variants associated with colorectal cancer prognosis. Carcinogenesis, 2013, 34, 2286-2291.	2.8	18

#	Article	IF	CITATIONS
109	Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies. Journal of the National Cancer Institute, 2013, 105, 878-886.	6.3	25
110	Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2013, 45, 842-864.	1.8	498
111	BMP2 / BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis, 2013, 34, 314-318.	2.8	14
112	A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12. BMC Genomics, 2013, 14, 55.	2.8	36
113	Abstract 1334: Implication of the 3â $\!$ UTR region of TGFβR1 with MSS HNPCC and sporadic colorectal cancer , 2013, , .		0
114	Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. New England Journal of Medicine, 2012, 366, 697-706.	27.0	763
115	Recurrent Testicular Germ Cell Tumors in a Family With MYH-Associated Polyposis. Journal of Clinical Oncology, 2012, 30, e216-e217.	1.6	4
116	Susceptibility genetic variants associated with early-onset colorectal cancer. Carcinogenesis, 2012, 33, 613-619.	2.8	35
117	Seeking genetic susceptibility variants for colorectal cancer: the EPICOLON consortium experience. Mutagenesis, 2012, 27, 153-159.	2.6	9
118	Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut, 2012, 61, 865-872.	12.1	172
119	A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer. PLoS ONE, 2012, 7, e45357.	2.5	164
120	Serrated polyposis syndrome: Molecular, pathological and clinical aspects. World Journal of Gastroenterology, 2012, 18, 2452.	3.3	58
121	Clinical and Molecular Features of the Hyperplastic Polyposis Syndrome. Gastroenterology, 2011, 140, S-260.	1.3	1
122	Identification of Mirnas and Their Gene Targets Differentially Expressed in Microsatellite Stable and Unstable Colorectal Cancers Through an Integrated Analysis. Gastroenterology, 2011, 140, S-819.	1.3	0
123	5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer. Gastroenterology, 2011, 140, 1174-1181.	1.3	185
124	Comparison Between Universal Immunohistochemistry for Mismatch Repair Proteins Versus Revised Bethesda Guidelines in the Detection of Patients With Lynch Syndrome. Gastroenterology, 2011, 140, S-97.	1.3	3
125	Differential Features of Colorectal Cancer (CRC) in Patients With Probable Non-Sporadic Mismatch Repair Deficiency Without Germline Mutation. Gastroenterology, 2011, 140, S-190-S-191.	1.3	0
126	Increased Line-1 Hypomethylation is a Unique Feature of Early-Onset Colorectal Cancer (CRC). Gastroenterology, 2011, 140, S-820-S-821.	1.3	1

#	Article	IF	CITATIONS
127	Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome. BMC Medical Genetics, 2011, 12, 12.	2.1	7
128	Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer, 2011, 11, 339.	2.6	38
129	Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. Inflammatory Bowel Diseases, 2011, 17, 1641-1650.	1.9	44
130	Validation Microsatellite Path Score in a Population-Based Cohort of Patients With Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 3374-3380.	1.6	18
131	Colorectal Cancers with Microsatellite Instability Display Unique miRNA Profiles. Clinical Cancer Research, 2011, 17, 6239-6249.	7.0	112
132	Extrapyramidal signs predict the development of overt hepatic encephalopathy in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 519-525.	1.6	10
133	Aberrant Gene Promoter Methylation Associated with Sporadic Multiple Colorectal Cancer. PLoS ONE, 2010, 5, e8777.	2.5	59
134	Colorectal Cancer Susceptibility Quantitative Trait Loci in Mice as a Novel Approach to Detect Low-Penetrance Variants in Humans: A Two-Stage Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 619-623.	2.5	12
135	EPCAM Germ Line Deletions as Causes of Lynch Syndrome in Spanish Patients. Journal of Molecular Diagnostics, 2010, 12, 765-770.	2.8	26
136	Brain edema dynamics in patients with overt hepatic encephalopathyA magnetic resonance imaging study. NeuroImage, 2010, 52, 481-487.	4.2	61
137	Aberrant DNA Methylation in Hereditary Nonpolyposis Colorectal Cancer Without Mismatch Repair Deficiency. Gastroenterology, 2010, 138, 1854-1862.e1.	1.3	95
138	Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer Phenotype. Gastroenterology, 2010, 139, 788-796.e6.	1.3	47
139	Methylation Analysis of MLH1 Improves the Selection of Patients for Genetic Testing in Lynch Syndrome. Journal of Molecular Diagnostics, 2010, 12, 498-504.	2.8	62
140	Single Nucleotide Polymorphisms in the Wnt and BMP Pathways and Colorectal Cancer Risk in a Spanish Cohort. PLoS ONE, 2010, 5, e12673.	2.5	24
141	Colorectal cancer prognosis twenty years later. World Journal of Gastroenterology, 2010, 16, 862-7.	3.3	28
142	Utility of p16 Immunohistochemistry for the Identification of Lynch Syndrome. Clinical Cancer Research, 2009, 15, 3156-3162.	7.0	17
143	Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2009, 15, 508-514.	1.9	46
144	Association of MUTYH and MSH6 germline mutations in colorectal cancer patients. Familial Cancer, 2009, 8, 525-531.	1.9	16

#	Article	IF	CITATIONS
145	The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. European Journal of Cancer, 2009, 45, 365-373.	2.8	179
146	Deep sedation with propofol does not precipitate hepatic encephalopathy during elective upper endoscopy. Gastrointestinal Endoscopy, 2009, 70, 262-268.	1.0	47
147	602 Fecal Immunochemical Test Is More Cost-Effective Than Guaiac Fecal Occult Blood Test. Comparison Between Two Colorectal Cancer Screening Programs. Gastroenterology, 2009, 136, A-97.	1.3	0
148	Transgenic Expression of VEGF in Intestinal Epithelium Drives Mesenchymal Cell Interactions and Epithelial Neoplasia. Gastroenterology, 2009, 136, 596-606.e4.	1.3	7
149	Validation and Extension of the PREMM1,2 Model in a Population-Based Cohort of Colorectal Cancer Patients. Gastroenterology, 2008, 134, 39-46.	1.3	57
150	Molecular Information Defines a New Entity of Hereditary Colorectal Cancer. Gastroenterology, 2008, 134, 888-889.	1.3	4
151	Obesity and Fat Distribution Imply a Greater Systemic Inflammatory Response and a Worse Prognosis in Acute Pancreatitis. Pancreatology, 2008, 8, 257-264.	1.1	93
152	Reelin is overexpressed in the liver and plasma of bile duct ligated rats and its levels and glycosylation are altered in plasma of humans with cirrhosis. International Journal of Biochemistry and Cell Biology, 2008, 40, 766-775.	2.8	27
153	A Prospective, Multicenter, Population-Based Study of BRAF Mutational Analysis for Lynch Syndrome Screening. Clinical Gastroenterology and Hepatology, 2008, 6, 206-214.	4.4	85
154	Brain cholinergic impairment in liver failure. Brain, 2008, 131, 2946-2956.	7.6	88
155	Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer. Gut, 2007, 56, 1714-1718.	12.1	85
156	Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer. Carcinogenesis, 2007, 28, 1687-1691.	2.8	16
157	Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repair–Deficient Colorectal Tumors. Journal of the National Cancer Institute, 2007, 99, 244-252.	6.3	157
158	Identification of MYH Mutation Carriers in Colorectal Cancer: A Multicenter, Case-Control, Population-Based Study. Clinical Gastroenterology and Hepatology, 2007, 5, 379-387.	4.4	141
159	Sedation with Propofol in Endoscopy Is Safe in Cirrhotic Patients and Does Not Induce Hepatic Encephalopathy. Gastrointestinal Endoscopy, 2007, 65, AB314.	1.0	Ο
160	Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology, 2007, 45, 879-885.	7.3	282
161	Detection of Metachronous Neoplasms in Colorectal Cancer Patients: Identification of Risk Factors. Diseases of the Colon and Rectum, 2007, 50, 971-980.	1.3	64
162	Detection of BRAF V600E Mutation in Colorectal Cancer. Journal of Molecular Diagnostics, 2006, 8, 540-543.	2.8	136

#	Article	IF	CITATIONS
163	Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. Hepatology, 2006, 43, 444-453.	7.3	38
164	Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis. Hepatology, 2006, 43, 1257-1266.	7.3	147
165	Cyclooxygenase 2 Expression in Colorectal Cancer with DNA Mismatch Repair Deficiency. Clinical Cancer Research, 2006, 12, 1686-1692.	7.0	35
166	Clinical Performance of Original and Revised Bethesda Guidelines for the Identification of MSH2/MLH1 Gene Carriers in Patients with Newly Diagnosed Colorectal Cancer: Proposal of a New and Simpler Set of Recommendations. American Journal of Gastroenterology, 2006, 101, 1104-1111.	0.4	36
167	Animal Models in the Study of Episodic Hepatic Encephalopathy in Cirrhosis. Metabolic Brain Disease, 2005, 20, 399-408.	2.9	24
168	Differential Features of Colorectal Cancers Fulfilling Amsterdam Criteria without Involvement of the Mutator Pathway. Clinical Cancer Research, 2005, 11, 7304-7310.	7.0	119
169	Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal Cancer. JAMA - Journal of the American Medical Association, 2005, 293, 1986.	7.4	457
170	Clinical significance of extrapyramidal signs in patients with cirrhosis. Journal of Hepatology, 2005, 42, 659-665.	3.7	28
171	Defective Mismatch-Repair Colorectal Cancer. American Journal of Clinical Pathology, 2004, 122, 389-394.	0.7	46
172	Synchronous Colorectal Neoplasms in Patients With Colorectal Cancer: Predisposing Individual and Familial Factors. Diseases of the Colon and Rectum, 2004, 47, 1192-1200.	1.3	55
173	Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain. European Journal of Gastroenterology and Hepatology, 2004, 16, 39-45.	1.6	72
174	Defective Mismatch-Repair Colorectal Cancer Clinicopathologic Characteristics and Usefulness of Immunohistochemical Analysis for Diagnosis. American Journal of Clinical Pathology, 2004, 122, 389-394.	0.7	26
175	Mismatch repair deficient colorectal cancer. Clinico-Pathological characteristics and relevance on chemotherapy response and survival. Gastroenterology, 2003, 124, A238.	1.3	0
176	Minimal Hepatic Encephalopathy and Extrapyramidal Signs in Patients With Cirrhosis. American Journal of Gastroenterology, 2003, 98, 1599-1604.	0.4	40
177	Relationship between extrapyramidal signs and minimal hepatic encephalopathy in compensated liver cirrhosis. Journal of Hepatology, 2002, 36, 203.	3.7	0
178	Infection by genotype 5a of HCV in a district of southeast Spain. American Journal of Gastroenterology, 2001, 96, 3042-3043.	0.4	32
179	D-lactic acidosis associated with use of medium-chain triglycerides. Lancet, The, 1995, 346, 314.	13.7	10